We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Indian Diagnostic Company Transasia Bio-Medical Acquires Pliva Lachema Diagnostica

By LabMedica International staff writers
Posted on 20 Oct 2009
Print article
An Indian clinical diagnostics company, Transasia Bio-Medicals Ltd. (Mumbai, India) has acquired Pliva Lachema Diagnostika (Brno, Czech Republic). The acquisition will bring advanced technology within reach for India's vast population.

The acquisition provides an opportunity for Transasia and ERBA to introduce newer products to the swiftly developing markets of Asia. Transasia and its 100% German subsidiary, ERBA Diagnostics Mannheim GmbH (Germany) have a team of experienced marketing and service professionals and a large distribution network. It markets products in countries, which include Italy, Germany, France, China, Turkey, Russia, and around the globe.

PLIVA Lachema Diagnostika develops, produces, and markets in vitro diagnostics (IVD) products for urine analysis, biochemistry, and microbiology. The company has an extensive marketing and distribution network in the countries of Central and Eastern Europe, which will complement the current market potential and product lines of Transasia and ERBA Mannheim

Lachema's customers in Central and Eastern Europe will have access to Transasia's large product range in clinical chemistry, immunoturbidimetry, and immunology. Transasia Bio-Medicals Ltd. and ERBA Diagnostics Mannheim intend to invest more than US$1 million in Lachema to increase its manufacturing capacities and add new quality, affordable, wide spectrum products in the near future.

Related Links:
Transasia Bio-Medicals Ltd.
Pliva Lachema Diagnostika


New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Creatine Kinase-MB Assay
CK-MB Test
New
Typhoid Rapid Test
OnSite Typhoid IgG/IgM Combo Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.